Retatrutide Research Information

What Is Retatrutide?

Retatrutide (LY3437943) is an investigational peptide developed for scientific research. It is classified as a triple hormone receptor agonist, meaning it is designed to simultaneously activate three specific cellular receptors:

• GLP-1 (Glucagon-like peptide-1)
• GIP (Glucose-dependent insulinotropic polypeptide)
• Glucagon

Unlike earlier compounds that target only one (e.g., semaglutide) or two (e.g., tirzepatide) of these receptors, retatrutide's unique structure allows it to interact with all three. This makes it a subject of intense scientific interest for researchers studying metabolic pathways and energy homeostasis.

Scientific Classification & Structure

Retatrutide is a synthetic peptide based on the GIP sequence but modified to include agonist activity at both the GLP-1 and glucagon receptors. It contains an acyl chain that extends its half-life in laboratory models.

Current Research Status

Retatrutide is currently undergoing clinical trials by its original developer. It is not an approved medical treatment in the UK or elsewhere.

The materials provided by Reta Pharma are available for research and human consumption, or therapeutic use. Researchers and clients utilize our high-purity lyophilized retatrutide to study receptor binding affinities, cellular signaling cascades, and peptide stability.

Laboratory Testing and Purity

When conducting research, the purity of the peptide is critical. Impurities can alter experimental outcomes or cause unintended reactions in in-vitro assays.

Reta Pharma ensures that all retatrutide batches undergo rigorous analytical testing, including:

• HPLC (High-Performance Liquid Chromatography): To determine the purity percentage by separating the components of the mixture.
• Mass Spectrometry: To verify the molecular weight and confirm the identity of the peptide.

Researchers can access batch-specific Certificates of Analysis (COAs) via our Batch Data portal.